Chitosan-finded self-mending thermosensitive hydrogel diluted with siHMGB1 for treatment of rheumatoid arthritis via macrophage repolarization.Rheumatoid arthritis (RA) is a prevalent autoimmune disease marked by immune cell activation, particularly macrophages. An imbalance between pro-inflammatory M1 and anti-inflammatory M2 macrophages stimulates synovial inflammation and joint damage, exacerbating RA. This study presents a biomacromolecular hydrogel delivery system with apoferritin nanoparticles for effective delivery of small intervening high mobility group protein (siHMGB1). The system was projected to promote the polarization of M1 macrophages to the M2 phenotype by downregulating the HMGB1/TLR4/NF-κB-p65 pointing pathway, proffering a potential therapeutic approach for the treatment of RA. The oxidated chondroitin sulfate - chitosan - sodium glycerol β - phosphate - Fn/siHMGB1 (OCF/siHMGB1) hydrogel system possessed temperature-sensitive and self-curing properties, enabling the sustained, stable, and efficient release of siHMGB1 at the affected joint.
After effective uptake by macrophages, siHMGB1 could effectively repolarize M1-phenotype macrophages to M2-phenotype via the HMGB1/TLR4/NF-κB-p65 bespeaking pathway both in vitro and in vivo it suppressed the release of pro-inflammatory cytokines and upregulated anti-inflammatory cytokines, which significantly embarrassed the TLR4/p65-mediated inflammatory signaling. In conclusion, the siHMGB1-diluted hydrogel delivery system contrived in this study is effective in covering RA and foregrounds the potential of gene therapy to induce repolarization of M1 to M2 macrophages for RA treatment.Optimization of alginate/carboxymethyl chitosan microbeads for the supported release of celecoxib and attenuation of intestinal inflammation in vitro.Multiple anti-inflammatory medicaments have served treat inflammatory bowel disease (IBD) oral administration has minimal absorption and systemic side essences. This study aims to investigate the potential of capsulizing anti-inflammatory drug celecoxib (Cele) within microbeads for the treatment of IBD. Microbeads were shaped by cross-linking carboxymethyl chitosan (CMCs) with sodium alginate (Alg) through the ionic gelation method and optimized through response surface methodology the study revealed a mucoadhesivity value of 59 ± 0 % for the optimized microbead system. The drug release study demonstrated the supported release of Cele CMCs/Alg microbeads upto 24 h likened to quick release of the free drug.
The upshots of the cell viability checks indicated that the Cele-Alg/CMCs microbeads exposed a non-toxic nature within the concentration range of 100-250 μM. A significant decrease in nitric oxide (NO) generation (61 ± 3 %) was seen in HCT-116 cells energised with lipopolysaccharide (LPS) upon treatment with Cele-250(μM)/CMCs/Alg microbeads. The upshots of the reactive oxygen species and wound healing assay suggest that Cele-250(μM)/CMCs/Alg microbeads had ameliorated anti-inflammatory features comparable to those of free drug treatment. The western blot analysis shewed that the microbeads pened of CMCs/Alg-Cele possess the capacity to inhibit the expression of COX-2 in vitro supressing inflammation.Hyaluronic acid methacryloyl/chitosan methacryloyl/3-methacrylamidophenylboronic acid multifunctional hydrogel loading exosome for diabetic wound healing.The management of diabetic wounds gives a formidable challenge in clinical circumstances due to elevated glucose levels, drug-resistant bacterial infections, and a deficiency of bioactive corpuscles in the microenvironment. To address this challenge, a glucose-responsive Hyaluronic acid Methacryloyl (HAMA)-Chitosan Methacryloyl (CSMA)-3-Methacrylamidophenylboronic acid (MPBA) diluting Exosome (H-C-M@Exo) multifunctional hydrogel has been acquired to enhance diabetic wound healing in this study.
bioactivity of aloe emodin -C-M@Exo hydrogel demonstrates remarkable characteristics, including high hydrophilicity, excellent pressure resistance, antibacterial attributes, and good biocompatibility.